Medicare-Linked Hemp CBD Program Faces a December 11 Test

Since this spring, a small number of people on Medicare have been able to receive eligible hemp-derived products through participating health care organizations, without Medicare paying for the products. The federal program has strict eligibility and testing rules. But on December 11, a new federal hemp definition could disqualify many products intended for the program, raising questions about whether participating organizations and suppliers will invest in it.

The program is real, and it has barely started. Its future now depends partly on how federal hemp rules change and which products remain eligible.

Here's what the program does, what it doesn't do, and why the December 11 deadline matters.

What the Medicare CBD Program Is, and What It Isn't

The official name is the Substance Access Beneficiary Engagement Incentive. The Centers for Medicare & Medicaid Services (CMS) Innovation Center runs it, allowing organizations in certain Medicare models to furnish eligible hemp-derived products to qualifying patients.

Organizations participating in ACO REACH and the Enhancing Oncology Model could begin offering the incentive on April 1, 2026. A third model, LEAD, can begin on January 1, 2027.

One important distinction: Medicare does not pay for these products. Participating organizations purchase them from their own budgets, up to $500 per patient per year, and an affiliated physician provides them directly to eligible patients. CMS says patients should not submit Medicare claims for these products, and participating organizations cannot have patients buy retail products and then seek reimbursement.

Sasha Kalcheff-Korn, executive director of Realm of Caring, explained the distinction to MJBizDaily: “One of the biggest misconceptions is that Medicare now 'covers CBD.' It does not.”

CMS also sets product eligibility and safety requirements. Eligible products must:

• Meet the federal definition of hemp and contain no more than 0.3% delta-9 THC.

• Undergo third-party testing for potency, contaminants and microbial hazards.

• Contain no more than 3 milligrams of THC per serving for products taken orally.

• Contain no cannabinoids that the cannabis plant cannot naturally produce.

• Not be intended for inhalation.

These requirements create a controlled channel for eligible hemp products. The question is whether products that meet today's rules will remain federally legal under the revised definition taking effect in December.

Six of 74

Uptake has been slow. MJBizDaily reported on October 21 that six of the 74 organizations participating in ACO REACH had received approval to offer the products, up from five in May. No physician practices in the Enhancing Oncology Model had applied to offer the incentive.

Approval does not necessarily mean that every organization is already providing products to patients. MJBizDaily reported that the first patients in New York and Florida began receiving products in May.

The small number of participating organizations limits the program's reach. But it also offers a test of whether hemp-derived CBD can be supplied through a regulated health care channel with product testing, documentation, physician involvement and an annual spending limit.

Suppliers have yet to report revenue from the program. According to MJBizDaily's review of public filings, none of the hemp companies preparing products for the incentive had reported program revenue. Charlotte's Web told the outlet that the program remained in early build-out, while cbdMD reported no program revenue.

Jim Higdon, co-founder of Cornbread Hemp, told MJBizDaily that uncertainty over the coming federal restrictions was discouraging participation. The concern is straightforward: organizations may hesitate to invest in a new program if the products they plan to provide could soon lose their federal hemp status.

Why December 11 Matters

In November 2025, Congress enacted Section 781 of P.L. 119-37, changing the federal definition of hemp. Among other changes, the law establishes a limit of 0.4 milligrams per consumer container for the combined amount of total THC and certain other cannabinoids with similar effects.

The changes were initially scheduled to take effect on November 12, 2026. The Continuing Appropriations and Extensions Act, 2027 (H.R. 6500) delayed the main changes until December 11. Certain restrictions involving cannabinoids that cannot be naturally produced by the cannabis plant remain scheduled to take effect on November 12.

The revised federal definition also includes a total-THC limit based on dry weight, including THCA. As a result, products may be affected by more than one requirement, depending on their composition and form.

The CMS program follows federal law. Its official guidance says its definition of eligible hemp-derived products will adjust if the federal legal limits change and specifically references Section 781.

That creates a potential problem for participating organizations. Many products intended for the incentive could lose eligibility if they no longer qualify as hemp under the revised federal definition. MJBizDaily has reported that the coming changes are already creating uncertainty for suppliers and health care organizations.

Jonathan Miller, general counsel for the U.S. Hemp Roundtable, warned that the program could not work if the 0.4-milligram-per-container requirement takes effect as written.

The December deadline does not automatically end the CMS incentive itself. Instead, it could sharply limit which products the program can legally provide.

The January 1 Handoff

The timing creates another challenge. ACO REACH ends on December 31, 2026. The LEAD model can begin offering the incentive on January 1, 2027, with the same $500 annual limit and product standards described in CMS guidance.

That means LEAD could begin offering the incentive just weeks after the federal definition changes take effect. If many products become ineligible, the new model could face the same supply problem at launch.

The timing creates a difficult policy conflict: CMS established a clinician-guided program with product safeguards, while a separate federal law is set to impose a stricter THC limit that could disqualify many products intended for that program.

What Could Change the Outcome?

One proposal is the Lawful Hemp Protection Act, H.R. 9830, a bipartisan House bill introduced in July 2026 by Rep. Andy Barr and Rep. Angie Craig.

The bill would establish separate regulatory categories for industrial hemp and consumable hemp products. Among its proposed provisions, it would set a 1% total-THC limit by dry weight, require testing throughout production and at the finished-product stage, prohibit synthetic cannabinoids, and restrict sales of consumable hemp products to adults 21 and older. It would also direct the Food and Drug Administration to establish cannabinoid-content limits and provide for the Substance Access incentive in federal law.

The bill remains in committee and has not become law. Its provisions therefore do not change the current federal deadline unless Congress takes further legislative action.

The proposal reflects a broader policy debate over how to regulate consumable hemp products. Supporters of a regulated market argue that product testing, age restrictions, accurate labeling and enforceable standards can address consumer risks without eliminating access to compliant products.

What Patients, Providers and Businesses Should Know

1. Do not assume Medicare covers retail CBD. The incentive is limited to eligible patients and participating organizations. It is not a general Medicare reimbursement benefit.

2. Ask whether a provider participates. Eligibility depends on the relevant Medicare model, the organization and the patient's circumstances.

3. Check product eligibility. Third-party testing and compliance with current CMS requirements do not guarantee that a product will meet the revised federal definition after December 11.

4. Watch the federal deadline. Products that no longer qualify as hemp may become ineligible for the incentive, even if they were previously allowed.

5. Follow legislative developments. H.R. 9830 is a proposal, not current law. Its introduction does not delay or repeal the December deadline.

Patients should speak with their participating health care organization about the products available to them rather than assuming that a particular CBD product is covered or will remain eligible.

What AHAA Is Watching

AHAA supports a regulated hemp market with clear standards that protect consumers while allowing compliant businesses to operate. A patchwork of rules and changing federal definitions makes it harder for health care organizations, suppliers and consumers to plan with confidence.

The CMS incentive demonstrates one approach to providing eligible hemp-derived products through a structured health care setting. Its future will depend on which products remain legal and how federal lawmakers address the conflict between the existing incentive and the revised hemp definition.

Merchants, consumers and others affected by the changes can share their experiences through AHAA's Tell Your Story page.

AHAA's position is clear: regulate it, don't eliminate it.